Microvascular Disease in Diabetes PDF

Foreword to: Microvascular Disease in Diabetes xv
Editor Biography xvii
List of Contributors xix
1 Introduction 1
Andrea Giustina and Stefano Frara
References
2 Pathophysiology 5
Francesco Tecilazich
Introduction
Anatomo-
Physiology of Microvessels 5
Regulation
of Microvascular Tone 6
Endothelial-Dependent Vasodilation 6
Endothelial-Independent Vasodilation 6
Nerve Axon Reflex (NARV) 7
Myogenic Response 7
Functional Hyperemia 7
Venoarteriolar Response (VAR) 8
Structural
Changes in the Microcirculation 8
Functional
Changes in the Microcirculation 8
Endothelial Dysfunction 8
VSMC Dysfunction 9
NARV Impairment 9
Defective Myogenic Response 10
Reduced Functional Hyperemia 10
Endothelial Dysfunction 11
Role of the Immune System and Leukostasis 11
Role of Hyperglycemia 12
AGEs 12
Polyol Pathway 12
Oxidative Stress 13
PKC 13
Transforming Growth Factor (TGF)-β 14
Hexosamine Pathway 14
Contents
viii Contents
PARP 14
ET-1 14
Vasoconstrictor Prostanoid Synthesis 15
Role of Insulin Resistance 15
Role of Inflammation 15
References
3 Genetics of Diabetic Microvascular Disease 23
Niina Sandholm and Carol Forsblom
Introduction
Genetics
of DKD 23
Heritability of DKD 23
Candidate Genes for DKD 24
Linkage Studies for DKD 25
Genome-Wide Association Studies on DKD 25
Sequencing Efforts for DKD 29
Genetics
of Diabetic Retinopathy 30
Heritability of Diabetic Retinopathy 30
Candidate Genes for Diabetic Retinopathy 30
Linkage Studies for Diabetic Retinopathy 31
GWAS on Diabetic Retinopathy 31
Sequencing Efforts for Diabetic Retinopathy 33
Genetics
of Diabetic Neuropathy 33
Heritability of Diabetic Neuropathy 33
Candidate Genes for Diabetic Neuropathy 33
GWASs on Diabetic Neuropathy 34
Future
Directions 34
Larger Studies Are Needed 34
How to Define the Phenotype? 35
Variability in the Phenotypic Definitions 35
Criteria for Controls 36
Do Genetics of Microvascular Complications in T1D and T2D Differ? 36
Low-Frequency and Rare Variants May Affect Diabetic Complications 36
Sequencing of Rare and Low-Frequency Variants 36
Linkage Analysis with GWAS Data 37
Genetics May Reveal Biology and Infer Causality 37
Conclusions
References
4 Epigenetics of Diabetic Microvascular Disease 45
Luciano Pirola
Diabetic
Complications Include Microvascular and Macrovascular Injury 45
The
Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Study in Type 1 Diabetic
Patients, and the UKPDS Study in Type 2 Diabetic Patients,
Support the Existence of the Hyperglycemic Memory Phenomenon 46
Contents ix
DCCT/EDIC Study 46
The UKPDS Study 46
Models
of Hyperglycemic Memory 47
Animal Models 47
Cell Culture Models 48
The
“Epigenetic Code” 48
DNA Methylation 49
Histone Methylation in Models of Hyperglycemic Variability 49
Epigenetic Changes in Microvascular Models of Glycemic Memory 50
miRNAs
Contribute to the Control of Glucose Homeostasis and Are
Dysregulated in Diabetes 52
Future
Prospects 52
References
5 Diabetic Retinopathy – Clinical 59
Francesco Bandello, Rosangela Lattanzio, Alessandro Marchese,
and Emanuela Aragona
Introduction
Epidemiology
Screening
Risk
Factors 61
Clinical
Patterns 61
Non-Proliferative Diabetic Retinopathy (NPDR) 61
Clinical Findings 62
Diagnostic Tools 64
Treatment Strategies 65
Proliferative Diabetic Retinopathy (PDR) 65
Clinical Findings 65
Diagnostic Tools 67
Treatment Strategies 67
Diabetic
Macular Edema (DME) 69
Classification 70
Clinical Findings 71
Diagnostic Tools 71
Treatment Strategies 71
Conclusions
73eferences
6 Diabetic Retinopathy – Research 79
Gopalan Gnanaguru
Retina and Induction of Hyperglycemia 79
Hyperglycemia
and Retinal Microvasculature 80
Hyperglycemia
and Reactive Gliosis 80
Hyperglycemia
and Neurodegeneration 81
Hyperglycemia
and Inflammation 81
References
82
x Contents
7 Diabetic Nephropathy – Clinical 85
Gianpaolo Zerbini
Epidemiology
85
Natural
History 86
Stages
of DN 86
Morphologic
Changes 87
Pathophysiology
88
Clinical
Course 89
Treatment
90
Primary
Prevention 90
Secondary
Prevention 91
Tertiary
Prevention 91
Perspectives
91
References
92
8 Diabetic Nephropathy – Research 97
Silvia Maestroni and Gianpaolo Zerbini
Essential
Hypertension and DN 97
Role
of Genetics in the Pathogenesis of DN 99
Polyol
Pathway and Non-Enzymatic Glycation 100
Environment
100
Perspectives
101
Sodium–Glucose Cotransporter-2 (SGLT2) and DN 101
B7-1 and DN 101
Animal
Models 102
DN
in Induced Model of Type 1 Diabetes Mellitus (T1DM) 102
DN
in Spontaneous Model of T1DM 103
Ins2Akita Mice 103
Non-
Obese Diabetic (NOD) Mice 104
OVE26
Friend leukemia virus B (FVB) Mice 104
DN
in Spontaneous Models of T2DM 105
db/db Mice 105
References
105
9 Diabetic Neuropathy – Clinical 111
Christopher H. Gibbons
Introduction
111
Classification
of Diabetic Neuropathies 111
Distal Symmetric Polyneuropathy (DSPN) 112
Diagnosis 113
Management 113
Small Fiber Neuropathy 114
Diagnosis 115
Management 115
Autonomic Neuropathy 116
Diagnosis 117
Contents xi
Management 117
Treatment-Induced Neuropathy of Diabetes (TIND) 119
Diagnosis 119
Management 120
Diabetic Radiculoplexopathy 120
Diagnosis 120
Management 121
Mononeuropathies 121
Diagnosis 121
Management 121
Cranial Neuropathies 121
Diagnosis 121
Management 122
Screening
for Neuropathy 122
Summary
of Management of Diabetic Neuropathy 122
References
123
10 Diabetic Neuropathy – Research 129
Krish Chandrasekaran, Lindsay A. Zilliox, and James W. Russell
Basic
and Translational Research in Diabetic Neuropathy 129
Animal Models of Diabetic Neuropathy 129
Basic Pathophysiology of Diabetic Neuropathy 131
Changes in Redox Potential 131
Role of Mitochondrial Dysfunction in Diabetic Neuropathy 133
Protein Kinase C (PKC) and Neuropathy 137
Advanced Glycation End Products 137
Modifying Molecular Chaperones 138
Inflammation and Neuropathy 138
TGF-β and Neuropathy 138
Metabotropic Glutamate Receptors (mGluRs) and Oxidative Injury 139
Growth Factors and Diabetes 139
Clinical Research in Diabetic Neuropathy 140
Treatment of Hypertension 141
Improved Glycemic Control 141
Diet and Lifestyle Interventions 142
Alpha-Lipoic Acid 144
Benfotiamine and Neuropathy 145
Treatment of Neuropathic Pain 145
Acknowledgments
146
References
147
11 Diabetic Foot – Clinical 157
Cristian Nicoletti
Introduction
and Size of the Problem 157
Pathogenesis
of Diabetic Foot Complications 158
Neuropathy 158
xii Contents
Peripheral Vascular Disease 158
Other Risk Factors 159
Prevention
159
Treatment
160
Treatment
of Neuropathic Diabetic Foot Ulcers: Offloading 160
Treatment
of PAD: Revascularization 161
Diabetic
Foot Infections (DFIs) 163
Introduction 163
Diagnosis 163
Treatment 164
Wound
Healing 166
Debridement 166
Dressings 167
Topical Negative Pressure Wound Therapy (NPWT) 167
Other Topical Treatments 167
References
167
12 Diabetic Foot – Research 173
Georgios Theocharidis and Aristidis Veves
Introduction
173
Anatomy
of the Skin and Microcirculation 174
Structural
Changes in the Microcirculation 174
Functional
Changes in the Microcirculation 175
Functional
Changes in the Diabetic Foot 176
Vasodilation 176
Endothelium-Dependent Vasodilation 177
Endothelium-Independent Vasodilation 178
Nerve Axon Reflex 179
Mechanisms of Endothelial Dysfunction 180
Endothelial Dysfunction and Hyperglycemia 180
Endothelial Dysfunction and Insulin Resistance 182
Endothelial Dysfunction and Inflammation 183
Pathophysiology
of Diabetic Wound Healing 184
Hyperglycemia 184
Chronic Inflammation 184
Impaired Angiogenesis and Vasculogenesis 186
Hypoxia 186
Impaired Neuropeptide Signaling 186
Adjunctive
Treatment Options 186
Bioengineered Skin Substitutes 187
Growth Factors 187
Hyperbaric Oxygen Therapy 188
Negative Pressure Wound Therapy 188
Electrical Stimulation and Shockwave Therapy 189
Future
Therapeutic Perspectives 189
Contents xiii
Gene Therapies 189
Stem Cell Therapies 189
Norleu3-Angiotensin-(1–7) 190
Neuropeptides 190
Cytokine Inhibition 190
Conclusion
191
References
191
13 Coronary Microvascular Dysfunction in Diabetes – Clinical and Research 201
Guglielmo Gallone, Francesco Moroni, and Marco Magnoni
Introduction
201
Clinical Classification and Mechanisms of CMD 202
CMD in Diabetic Patients 203
Clinical
Assessment of CMD 205
Non-Invasive Imaging Technique for the Assessment of CMD 205
Transthoracic Doppler Evaluation 205
Contrast Echocardiography 206
Cardiovascular Magnetic Resonance (CMR) Imaging 206
Positron Emission Tomography (PET) 207
Invasive Techniques for the Evaluation of CBF 207
Indicator Dilution-Based Methods 207
Thermodilution 208
Gas Wash Out Method 208
Intracoronary Doppler Flow Wire 208
Treatment for CMD 210
The Effects of Glucose-Lowering Drugs on CMD 211
Future Perspectives for the Treatment of CMD in Diabetes 211
References
212
14 Cerebral Microvascular Disease in Diabetes – Clinical and Research 221
Eelco van Duinkerken and Richard G. IJzerman
Introduction
221
Postmortem
Studies of the Brain in Diabetes 222
Cerebral
Small Vessel Disease on MRI 223
MRI-
Measured Cerebral Small Vessel Disease in Type 1 Diabetic Patients 224
White Matter Hyperintensities 224
Cerebral Microbleeds 226
Summary 226
Type
2 Diabetes and Cerebral Small Vessel Disease 227
Lacunar Infarcts 227
White Matter Hyperintensities 228
Cerebral Microbleeds 230
Synthesis 230
Clinical
Impact of Cerebral Small Vessel Disease in Diabetes 231
Cognitive Functioning 231
xiv Contents
Stroke 233
Dementia 234
The
Influence of Microvascular Disease on the Structure and Functioning
of the Diabetic Brain 235
Type 1 Diabetes 236
Type 2 Diabetes 237
Conclusions
and Future Directions 239
References
240
Index 247
Microvascular Disease in Diabetes PDF Ebook

FRANCESCO TECILAZICH, MD, PhD, is a physician and scientist in the Endocrinology and Metabolic Diseases department of the Ospedale San Raffaele―Vita Salute San Raffaele University in Milan, Italy.